|
1
|
Chornokur G, Amankwah EK, Schildkraut JM
and Phelan CM: Global ovarian cancer health disparities. Gynecol
Oncol. 129:258–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang B, Cai FF and Zhong XY: An overview
of biomarkers for the ovarian cancer diagnosis. Eur J Obstet
Gynecol Reprod Biol. 158:119–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suh DH, Kim JW, Kim K, Kim HJ and Lee KH:
Major clinical research advances in gynecologic cancer in 2012. J
Gynecol Oncol. 24:66–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Despierre E, Lambrechts D, Neven P, Amant
F, Lambrechts S and Vergote I: The molecular genetic basis of
ovarian cancer and its roadmap towards a better treatment. Gynecol
Oncol. 117:358–365. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alvarez-Garcia I and Miska EA: MicroRNA
functions in animal development and human disease. Development.
132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Katz B, Tropé CG, Reich R and Davidson B:
MicroRNAs in ovarian cancer. Hum Pathol. 46:1245–1256. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly
KA, Calin GA, Li Z, Bast RC Jr and Le XF: Clinically relevant
microRNAs in ovarian cancer. Mol Cancer Res. 13:393–401. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao XQ, Liang B, Jiang K and Zhang HY:
Down-regulation of miR-655-3p predicts worse clinical outcome in
patients suffering from hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 21:748–752. 2017.PubMed/NCBI
|
|
15
|
Wu G, Zheng K, Xia S, Wang Y, Meng X, Qin
X and Cheng Y: MicroRNA-655-3p functions as a tumor suppressor by
regulating ADAM10 and β-catenin pathway in hepatocellular
carcinoma. J Exp Clin Cancer Res. 35:892016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Zang W, Du Y, Ma Y, Li M, Li P,
Chen X, Wang T, Dong Z and Zhao G: Mir-655 up-regulation suppresses
cell invasion by targeting pituitary tumor-transforming gene-1 in
esophageal squamous cell carcinoma. J Transl Med. 11:3012013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang P, Wang X, Zhou Y and Hou Y:
Analysis of the correlation between the expression of miR-655 and
esophageal cancer prognosis. Oncol Lett. 13:4691–4694. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lv ZD, Kong B, Liu XP, Jin LY, Dong Q, Li
FN and Wang HB: miR-655 suppresses epithelial-to-mesenchymal
transition by targeting Prrx1 in triple-negative breast cancer. J
Cell Mol Med. 20:864–873. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen W, Li HL, Liu L and Cheng JX:
Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors
in ovarian cancer. Eur Rev Med Pharmacol Sci. 21:2596–2603.
2017.PubMed/NCBI
|
|
21
|
Whynott RM, Manahan P and Geisler JP:
Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX
2) immunostaining in ovarian cancer. Eur J Gynaecol Oncol.
37:164–166. 2016.PubMed/NCBI
|
|
22
|
Li J, Li L, Li Z, Gong G, Chen P, Liu H,
Wang J, Liu Y and Wu X: The role of miR-205 in the VEGF-mediated
promotion of human ovarian cancer cell invasion. Gynecol Oncol.
137:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leng R, Zha L and Tang L: miR-718
represses VEGF and inhibits ovarian cancer cell progression. FEBS
Lett. 588:2078–2086. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Y, Zhang L, Liu WX and Wang K: VEGF
and SEMA4D have synergistic effects on the promotion of
angiogenesis in epithelial ovarian cancer. Cell Mol Biol Lett.
23:22018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang YQ, Guo RD, Guo RM, Sheng W and Yin
LR: MicroRNA-182 promotes cell growth, invasion, and
chemoresistance by targeting programmed cell death 4 (PDCD4) in
human ovarian carcinomas. J Cell Biochem. 114:1464–1473. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu H, Xiao Z, Wang K, Liu W and Hao Q:
miR-145 is downregulated in human ovarian cancer and modulates cell
growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys
Res Commun. 441:693–700. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou F, Chen J and Wang H: MicroRNA-298
inhibits malignant phenotypes of epithelial ovarian cancer by
regulating the expression of EZH2. Oncol Lett. 12:3926–3932. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Corney DC and Nikitin AY: MicroRNA and
ovarian cancer. Histol Histopathol. 23:1161–1169. 2008.PubMed/NCBI
|
|
29
|
Harazono Y, Muramatsu T, Endo H, Uzawa N,
Kawano T, Harada K, Inazawa J and Kozaki K: miR-655 is an
EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One.
8:e627572013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang HQ, Wang RJ, Diao CF, Li JW, Su JL
and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381,
and miR-655 inhibit pituitary tumor cell tumorigenesis and are
involved in a p53/PTTG1 regulation feedback loop. Oncotarget.
6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang M, Li Q, Pan Y, Wang H, Liu G and
Yin H: MicroRNA-655 attenuates the malignant biological behaviours
of retinoblastoma cells by directly targeting PAX6 and suppressing
the ERK and p38 MAPK signalling pathways. Oncol Rep. 39:2040–2050.
2018.PubMed/NCBI
|
|
32
|
Ji YN, Wang Q, Li Y and Wang Z: Prognostic
value of vascular endothelial growth factor A expression in gastric
cancer: A meta-analysis. Tumour Biol. 35:2787–2793. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Youssef NS and Said AM:
Immunohistochemical expression of CD117 and vascular endothelial
growth factor in retinoblastoma: Possible targets of new therapies.
Int J Clin Exp Pathol. 7:5725–5737. 2014.PubMed/NCBI
|
|
34
|
Yamaguchi R, Yano H, Iemura A, Ogasawara
S, Haramaki M and Kojiro M: Expression of vascular endothelial
growth factor in human hepatocellular carcinoma. Hepatology.
28:68–77. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wen L, Wang R, Lu X and You C: Expression
and clinical significance of vascular endothelial growth factor and
fms-related tyrosine kinase 1 in colorectal cancer. Oncol Lett.
9:2414–2418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Premalata CS, Umadevi K, Shobha K,
Anurekha M and Krishnamoorthy L: Expression of VEGF-A in epithelial
ovarian cancer: Correlation with morphologic types, grade and
clinical stage. Gulf J Oncolog. 1:49–54. 2016.PubMed/NCBI
|
